Metastatic extramammary Paget's disease treated with paclitaxel and trastuzumab combination chemotherapy

Journal of Dermatology

Volumn 36, Issue 8, 2009, Pages 457-461

  Takahagi, Shunsuke ^a   Noda, Hideki ^a   Kamegashira, Akiko ^a   Madokoro, Naoki ^a   Hori, Ikuko ^a   Shindo, Hajime ^a   Mihara, Shouji ^a   Hide, Michihiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Central nervous system metastasis; Extramammary Paget's disease; Human epidermal growth factor receptor 2 (HER2); Paclitaxel; Trastuzumab

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; MITOMYCIN C; PACLITAXEL; TRASTUZUMAB;

AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CENTRAL NERVOUS SYSTEM METASTASIS; DERMIS; DRUG WITHDRAWAL; HISTOPATHOLOGY; HUMAN; INGUINAL REGION; LOADING DRUG DOSE; LOW DRUG DOSE; LYMPHADENOPATHY; MALE; PAGET SKIN DISEASE; PERIPHERAL NEUROPATHY; SCROTUM; SKIN METASTASIS; TUMOR CELL;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM NEOPLASMS; GENITAL NEOPLASMS, MALE; HUMANS; MALE; PACLITAXEL; PAGET DISEASE, EXTRAMAMMARY; SKIN; SKIN NEOPLASMS;

EID: 68749119973     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2009.00676.x     Document Type: Article

References (7)

1. Bullock K, Blackwell K. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. Oncologist 2008 13 : 515 525.
2. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001 344 : 783 792.
3. Ogawa T, Nagashima Y, Wada H et al. Extramammary Paget's disease: analysis of growth signal pathway from the human epidermal growth factor receptor 2 protein. Hum Pathol 2005 36 : 1273 1280.
4. Takata M, Fujimoto A, Aoki H, Hatta N, Ooi A, Takehara K. erbB-2 overexpression but no activation of beta-Catenin gene in extramammary Paget's disease. J Invest Dermatol 1999 113 : 258 262.
5. Lin NU, Winer E. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007 13 : 1648 1655.
6. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2006 15 : 219 225.
7. Bendell JC, Domchek SM, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003 97 : 2972 2977.